Organic Pressurized Fluid Patents (Class 424/45)
-
Patent number: 9072667Abstract: A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes water, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free and substantially polymeric agent-free foamable composition.Type: GrantFiled: January 27, 2012Date of Patent: July 7, 2015Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
-
Patent number: 9050253Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.Type: GrantFiled: April 7, 2014Date of Patent: June 9, 2015Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
-
Publication number: 20150147280Abstract: An azeotrope-like mixture consisting essentially of chlorotrifluoropropene and at least one component selected from the group consisting of a C1-C3 alcohol, a C5-C6 hydrocarbon, a halogenated hydrocarbon, methylal, methyl acetone, water, nitromethane, and combinations thereof.Type: ApplicationFiled: January 30, 2015Publication date: May 28, 2015Inventors: Rajat Basu, Leslie Bement, Kane Cook, Ryan Hulse, Gary Knopeck, Hang T. Pham, Rajiv R. Singh, David J. Williams
-
Patent number: 9040024Abstract: An air treating composition for eliminating airborne malodors and/or sanitizing air in combination with a spray valve and actuator and spray performance parameters providing maximum dispersion of the composition is disclosed. The particles of the composition are small so that the active component is dispersed into air as a fine dispersion to provide more contact with malodors and to provide quick absorption of malodors and/or bacteria. The particle size of the composition is controlled through the valve and actuator dimensions, as well as the formulation requirements of the composition. The air treating composition includes water, a low molecular weight polyol, and a propellant. The composition may also include one or more adjuvants such as an emulsifier, a co-solvent, a fragrance, a corrosion inhibitor, a pH adjusting agent and the like.Type: GrantFiled: March 5, 2013Date of Patent: May 26, 2015Assignee: S.C. Johnson & Son, Inc.Inventors: Maciej K. Tasz, Richard S. Valpey, III, Paul A. Clark
-
Patent number: 9028854Abstract: A pesticidal composition comprising 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether; a hydrophobic organic solvent capable of dissolving 0.1-fold by weight of 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether at 0° C.; polyvinyl alcohol; a nonionic surfactant selected from the group consisting of alkoxylated castor oil, alkoxylated hydrogenated castor oil and alkoxylated hydrogenated castor oil fatty acid ester; and water, is excellent in storage stability.Type: GrantFiled: December 13, 2005Date of Patent: May 12, 2015Assignee: Sumitomo Chemical Company, LimitedInventor: Toshiyuki Tanedani
-
Publication number: 20150118164Abstract: A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.Type: ApplicationFiled: October 2, 2014Publication date: April 30, 2015Inventors: Dov Tamarkin, Helena Shifrin, Rita Keynan, Enbal Ziv, Tal Berman, David Schuz, Elana Gazal
-
Patent number: 9011882Abstract: The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.Type: GrantFiled: February 13, 2013Date of Patent: April 21, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Yohannes T. Ghebremariam, John P. Cooke
-
Patent number: 9011923Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurized metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.Type: GrantFiled: February 2, 2009Date of Patent: April 21, 2015Assignees: Innovata Biomed Limited, Vectura LimitedInventors: David Andrew Lewis, Christina Alexandra Keeble, Nicola Kim Whitfield, Tanya Church
-
Patent number: 9005584Abstract: Spray compositions are formulated with powders (e.g. corn starch) which improve skin feel, and also have a hydrophobically modified oxide additive (e.g. modified silica) to reduce the incidence of can/bottle clogging and sedimentation caused by the powder. The oxide is a mixed hydrophobic/hydrophilic oxide such as hydrophobicly modified fumed silica (e.g. silica dimethyl silylate). In one embodiment DEET can be delivered by such formulations.Type: GrantFiled: June 8, 2012Date of Patent: April 14, 2015Assignee: S.C. Johnson & Son, Inc.Inventor: John S. Trent
-
Publication number: 20150093338Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.Type: ApplicationFiled: October 8, 2014Publication date: April 2, 2015Inventor: Michael Farber
-
Patent number: 8992889Abstract: A freshening composition having a malodor control component, about 1% to about 5% of low molecular weight monohydric alcohols, and an aqueous carrier are provided. The composition is essentially free of any material that would soil or stain fabric. The composition may be delivered to fabrics and/or air. The malodor control component may include an effective amount of volatile aldehydes and/or an acid catalyst.Type: GrantFiled: April 7, 2011Date of Patent: March 31, 2015Assignee: The Procter & Gamble CompanyInventors: Ricky Ah-Man Woo, Steven Anthony Horenziak, Rhonda Jean Jackson, Zaiyou Liu, Michael-Vincent Nario Malanyaon, Jason John Olchovy, Christine Marie Readnour
-
Patent number: 8992890Abstract: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.Type: GrantFiled: February 13, 2012Date of Patent: March 31, 2015Assignee: Fidia Farmaceutici S.p.A.Inventors: Andrea Pastorello, Devis Galesso, Fabio Bettella
-
Publication number: 20150086489Abstract: A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C14-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.Type: ApplicationFiled: December 3, 2014Publication date: March 26, 2015Inventors: Thierry BOUYSSOU, Michael Paul PIEPER, Andreas SCHNAPP
-
Patent number: 8986658Abstract: The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis, as well as for prophylactic and/or cosmetic purposes.Type: GrantFiled: December 27, 2013Date of Patent: March 24, 2015Assignee: Intendis GmbHInventors: Klaus Graupe, Gerald Stadtler
-
Patent number: 8986738Abstract: A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase.Type: GrantFiled: March 31, 2009Date of Patent: March 24, 2015Assignee: NOVALIQ GmbHInventor: Hasso Meinert
-
Publication number: 20150079185Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Inventors: JOHN NICHOLAS STANIFORTH, MATTHEW MICHAEL GREEN, DAVID ALEXANDER VODDEN MORTON
-
Patent number: 8980226Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.Type: GrantFiled: September 14, 2012Date of Patent: March 17, 2015Assignee: Gilead Sciences, Inc.Inventors: William Baker, David MacLeod
-
Patent number: 8980228Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.Type: GrantFiled: March 4, 2013Date of Patent: March 17, 2015Assignee: Kate Somerville Skincare, LLCInventors: Kate Somerville, Fred Khoury
-
Patent number: 8980227Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.Type: GrantFiled: August 16, 2012Date of Patent: March 17, 2015Assignee: Kate Somerville Skincare, LLCInventors: Kate Somerville, Fred Khoury
-
Patent number: 8974771Abstract: This disclosure relates to an apparatus useful for the delivery of aerosols, such as those containing drugs, to the lungs or other locations in the body. The disclosure also relates to methods of administering an aerosol to the lungs or other locations in the body of a patient.Type: GrantFiled: March 9, 2010Date of Patent: March 10, 2015Assignee: Penn-Century, Inc.Inventor: Theodore J. Century
-
Patent number: 8940271Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.Type: GrantFiled: December 15, 2011Date of Patent: January 27, 2015Assignee: Abbott LaboratoriesInventors: Mark C. Heit, Antonio M. Benitz, Dennis F. Steadman, David M. Petrick
-
Patent number: 8940321Abstract: The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal.Type: GrantFiled: April 2, 2012Date of Patent: January 27, 2015Assignee: Otic Pharma Ltd.Inventor: Eran Eilat
-
Patent number: 8940319Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.Type: GrantFiled: June 1, 2012Date of Patent: January 27, 2015Assignee: Accentia Biopharmceuticals, Inc.Inventors: Francis E. O'Donnell, Angelos M. Stergiou
-
Publication number: 20150023888Abstract: The invention is drawn to a novel, early interventional use of a pharmaceutical composition wherein administration of said pharmaceutical composition pre-empts the onset of migraine headaches, preferably anytime in the migraine cycle prior to pain onset. The pharmaceutical composition preferably is administered via inhalation in order to provide therapy to the subject in a timely fashion, ideally in a non-clinical setting. The pharmaceutical composition may also be administered to a subject at risk for stroke.Type: ApplicationFiled: September 30, 2014Publication date: January 22, 2015Inventors: ROBERT O. COOK, PAUL L. DURHAM
-
Publication number: 20150017103Abstract: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.Type: ApplicationFiled: October 3, 2013Publication date: January 15, 2015Applicant: Foamix Ltd.Inventors: Dov Tamarkin, Meir Eini, Doron Friedman, Tal Berman, David Schuz
-
Publication number: 20150017104Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.Type: ApplicationFiled: July 17, 2014Publication date: January 15, 2015Inventors: Reinhard Vehring, Michael Steven Hartman, David Lechuga-Ballesteros, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Kumar Dwivedi
-
Publication number: 20150017247Abstract: Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting ?2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Inventors: Reinhard Vehring, Michael Steven Hartman, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Kumar Dwivedi
-
Patent number: 8927474Abstract: An aqueous compressed gas aerosol formulation in combination with a lined steel can, which may also optionally be tin plated, to provide corrosion stability, fragrance stability and color stability. An aerosol formulation of particular advantage for use is an air and/or fabric treatment formulation. The combination provides a compatibility which allows for the ability to use a broader fragrance pallet for the air and/or fabric treatment formulation which is aqueous based in major proportion. The formulation includes, in addition to an aqueous carrier, a fragrance, nonionic surfactant(s) or a blend of nonionic surfactant(s) and cationic surfactant(s), a compressed gas propellant(s), pH adjuster(s), and corrosion inhibitor(s). The formulation has a pH of about 8 to less than 10. The corrosion inhibitor(s) is(are) mild in strength and used in a minor amount.Type: GrantFiled: March 16, 2012Date of Patent: January 6, 2015Assignee: S.C. Johnson & Son, Inc.Inventor: Bhaveshkumar Shah
-
Publication number: 20140377365Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).Type: ApplicationFiled: June 18, 2014Publication date: December 25, 2014Inventors: Libo WU, Wiwik WATANABE
-
Publication number: 20140377189Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a stable solution formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).Type: ApplicationFiled: June 18, 2014Publication date: December 25, 2014Inventors: Libo WU, Wiwik WATANABE
-
Patent number: 8911711Abstract: Methods, devices, and systems are provided which include an aerosol generator and a pharmaceutical composition including a membrane selective for a charged ion configured to achieve a selected pH of a pulmonary tissue in a subject. The methods, devices, or systems which include the membrane may be configured to alter selectivity for the charged ion in response to a sensed condition in the pulmonary tissue.Type: GrantFiled: September 30, 2008Date of Patent: December 16, 2014Assignee: The Invention Science Fund I, LLCInventors: Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Dennis J. Rivet, Lowell L. Wood, Jr., Victoria Y. H. Wood
-
Publication number: 20140363384Abstract: Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate.Type: ApplicationFiled: August 25, 2014Publication date: December 11, 2014Applicant: CHIESI FARMACEUTICI S.p.AInventors: Sauro BONELLI, Francesca USBERTI, Enrico ZAMBELLI
-
Publication number: 20140363383Abstract: The stable aerosol solution formulations comprising glycopyrronium chloride are useful for administration to patients with COPD and other respiratory conditions.Type: ApplicationFiled: August 25, 2014Publication date: December 11, 2014Applicant: Chiesi Farmaceutici S.p.AInventors: Sauro BONELLI, Francesca Usberti, Enrico Zambelli
-
Patent number: 8900555Abstract: Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.Type: GrantFiled: July 27, 2007Date of Patent: December 2, 2014Assignee: Nektar TherapeuticsInventors: Mei-Chang Kuo, Michael Eldon, Yiqiong Yuan
-
Publication number: 20140348928Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20140348758Abstract: This invention relates to a solution formulation containing a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a pMDI comprising a canister containing the formulation.Type: ApplicationFiled: December 6, 2012Publication date: November 27, 2014Inventor: Xian-Ming Zeng
-
Publication number: 20140341955Abstract: Disclosed are methods of preparing stable gas-in-solution emulsions by particle adsorption via electrostatic interaction, and stable emulsions prepared by particle adsorption via electrostatic interaction. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature.Type: ApplicationFiled: May 17, 2013Publication date: November 20, 2014Inventors: Vance BERGERON, Jean-Thierry SIMONNET, Florence LEVY, Aurelie LAFUMA, Stephane SANTUCCI
-
Publication number: 20140328770Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.Type: ApplicationFiled: July 9, 2014Publication date: November 6, 2014Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
-
Patent number: 8877164Abstract: Aerosol solution formulation for use in an aerosol inhaler which includes at least one active ingredient selected from 20-ketosteroids and quinolinone derivatives, a propellant containing a hydrofluoroalkane, a cosolvent, and a specific amount of a sequestering agent that stabilizes the formulation. By way of example, the stabilizing agent may be phosphoric acid or sulphuric acid.Type: GrantFiled: February 24, 2006Date of Patent: November 4, 2014Assignee: Chiesi Farmaceutici S.p.A.Inventors: David Andrew Lewis, Brian John Meakin, Maurizio Delcanale, Fausto Pivetti
-
Publication number: 20140314684Abstract: The present invention provides a process for making a stabilized medical aerosol suspension formulation for administration by a pressurized metered dose inhaler.Type: ApplicationFiled: May 16, 2014Publication date: October 23, 2014Applicant: JAGOTEC AGInventors: Rudi Mueller-Walz, Lise-Marie Fueg
-
Patent number: 8865132Abstract: Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a single surfactant which, in the absence of a solvent, dissolves or disperses the water-insoluble component(s) and provides a homogenous blend in water which provides a stable compressed gas emulsion.Type: GrantFiled: August 22, 2013Date of Patent: October 21, 2014Assignee: S.C. Johnson & Son, Inc.Inventors: Richard S. Valpey, III, Paul A. Clark, Jessica A. Elwell (nee Heiser)
-
Publication number: 20140308214Abstract: The present invention relates to pharmaceutical compositions for inhalation comprising glycopyrrolate, a beta2-agonist, and optionally an inhaled corticosteroid; to a process for preparing such compositions and to the use of such compositions for the prevention and/or treatment of respiratory, inflammatory or obstructive airway disease.Type: ApplicationFiled: February 17, 2012Publication date: October 16, 2014Applicant: CIPLA LIMITEDInventors: Geena Malhotra, Shrinivas Madhukar Purandare
-
Publication number: 20140308215Abstract: An anhydrous antiperspirant composition comprising a dehydrated alum salt, a water soluble calcium salt, and a liquid carrier material comprising 50% or more by weight of hydrophobic oils.Type: ApplicationFiled: September 12, 2012Publication date: October 16, 2014Inventors: Michael Richard Baker, Neil Robert Fletcher, Kevin Ronald Franklin, Kirill Shafran
-
Patent number: 8858971Abstract: In one aspect, an epidermal coolant dispensable by an aerosol container includes a phase change material that changes phase between about 28-degrees and 40-degrees Celsius. The coolant also includes a solvent in which the phase change material is dissolved and a surfactant. The coolant may further include a propellant to express the product from the aerosol container. In another aspect, an epidermal coolant includes a porous material and a phase change material retained in the porous material. The phase change material has a melting point between about 0-degrees Celsius and about 65-degrees Celsius and is retained in the porous material when the phase change material is in either the solid or liquid phase.Type: GrantFiled: June 20, 2013Date of Patent: October 14, 2014Assignee: Exert Co.Inventor: Arvind M. Rao
-
Publication number: 20140294737Abstract: The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a danazol compound or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical product formulated for nasal administration. The product comprises a danazol compound or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 5, 2012Publication date: October 2, 2014Inventor: David Bar-Or
-
Publication number: 20140294738Abstract: The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical product comprising a DA-DKP containing composition.Type: ApplicationFiled: October 26, 2012Publication date: October 2, 2014Applicant: AMPIO PHARMACEUTICALS, INC.Inventor: David Bar-Or
-
Publication number: 20140286878Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.Type: ApplicationFiled: October 18, 2013Publication date: September 25, 2014Applicant: AstraZeneca ABInventors: Nayna Govind, Maria Marlow
-
Publication number: 20140286879Abstract: A pharmaceutical composition comprising: (a) a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; R2 is hydrogen, halogen, C1-4-alkyl, or O—C1-4-alkyl; and R3 is hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, or O—C1-4-alkylene-COO—C1-4-alkyl, or an enantiomer, mixture of enantiomers, or racemate thereof, or an acid addition salt with pharmacologically acceptable acids thereof, or a solvate or hydrate thereof; and (b) another active substance 2, wherein the molar ratio of the compound of formula 1 to the active substance 2 is 1:10 to 12:1.Type: ApplicationFiled: June 12, 2014Publication date: September 25, 2014Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Thierry BOUYSSOU, Michael Paul PIEPER, Andreas SCHNAPP
-
Publication number: 20140271494Abstract: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.Type: ApplicationFiled: January 22, 2014Publication date: September 18, 2014Applicant: FOAMIX LTD.Inventors: Dov Tamarkin, Rita Keynan, David Schuz, Tal Berman
-
Patent number: 8834848Abstract: A drug and device combination system used in a method for treatment of patients suffering from severe and oral corticosteroid-dependent asthma and other respiratory diseases requiring a treatment with orally administered steroids. The method for administration of the inhalable corticosteroid by a flow rate and volume regulated inhalation. The combination system of the inhalable corticosteroid and the device for regulating flow rate and volume of the inhalable corticosteroid and thus achieving delivery of said inhalable corticosteroid into the small airways of the lungs. The individually programmable device that assures safe and reproducible corticosteroid delivery compliant with treatment protocol.Type: GrantFiled: September 6, 2012Date of Patent: September 16, 2014Assignee: Activaero GmbH Research & DevelopmentInventors: Bernard Muellinger, Gerhard Scheuch, Thomas Hofmann, Philipp Kroneberg